Glenmark Launches Coronavirus COVID-19 Drug Tablet

Follow us

Glenmark Launches Coronavirus COVID-19 Drug Tablet 

Covid-19 drug FabiFlu, priced at Rs 103 per tablet
Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet.
The drug will be available as a 200 mg tablet at a maximum retail price (MRP)of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
FabiFlu is the first oral favipiravir-approved medication in India for the treatment of COVID-19, it said in a statement.
It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, it added.
The tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel, Glenmark said.
The Mumbai-based firm had on Friday received the manufacturing and marketing approval from the Drugs Controller General of India (DCGI).

GLENMARK PHARMACEUTICALS RECEIVES ANDA APPROVAL FOR CHLORZOXAZONE TABLETS USP, 375 MG AND 750 MG; GLENMARK’S FIRST ANDA APPROVAL OUT OF THEIR NEW U.S. FACILITY

Mumbai, India; May 27, 2020: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Chlorzoxazone Tablets USP, 375 mg and 750 mg. This marks Glenmark’s first ANDA approval out of their new North American manufacturing facility based in Monroe, North Carolina.
According to IQVIATM,1 sales data for the 12 month period ending March 2020, the Chlorzoxazone Tablets, 375 mg and 750 mg market2 achieved annual sales of approximately $20.9 million*.
Glenmark’s current portfolio consists of 163 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
—End—
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com
For more information:
Glenmark Media Contact

Madhurima Gupta Jain
Glenmark Pharmaceuticals, Mumbai, India
Tel: +91 22 4018 9606
Email: corpcomm@glenmarkpharma.com
1All brand names and trademarks are the property of their respective owners.
2Market includes brand and all available therapeutic equivalents
*IQVIATM National Sales Perspectives: Retail & Non-Retail, March 2020
Glenmark Life Sciences partners the world’s top 20 generic companies to supply them with a wide range of high-quality, industry-leading Active Pharmaceutical Ingredients (APIs).
We have steadily built scale in our product offerings & reach. Leveraging our state-of-the-art laboratories and manufacturing locations, we supply over 130 molecules to more than 700 customers across 65 countries. From product selection & development to commercialisation, we judiciously blend science, technology and economics to stay ahead of the curve.
In highly-regulated markets, our APIs have enabled several first-to-file offerings by our customers. We have a proven ability to spot and make the most of business opportunities ahead of the competition thus giving an edge to our customers in a competitive market. Glenmark Life Sciences is an independent unit of Glenmark Pharmaceuticals, a 40 year-old integrated, research-driven, global pharmaceutical organization committed to enriching lives.


Post a Comment

Previous Post Next Post